We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Deputy Director, Therapeutic Discovery, Sloan Kettering Institute
Get To Know Me
Dr. Scheinberg is a physician-scientist who specializes in the care of patients with leukemia and is also investigating new therapeutic approaches to cancer, both in the clinic and in the laboratory. His research is focused on discovering and developing novel, specific immunotherapeutic agents. These include monoclonal antibodies that target the cell surface of cancers, intracellular proteins, engineered cells, targeted radiopharmaceuticals that deliver radioactive particles including alpha particles or alpha particle nanogenerators, targeted nanodevices that selectively kill cancer cells, and therapeutic vaccines that target the oncogene products that cause the cancers.
Read more
Eight different therapeutic agents developed by Dr. Scheinberg in his laboratory have reached human clinical trials, including the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, and the first tumor-specific fusion oncogene product vaccines. His laboratory is also investigating cellular resistance mechanisms to these agents. Dr. Scheinberg has published more than 350 papers, chapters, and books in these fields.
Dr. Scheinberg currently holds the Vincent Astor Chair at Memorial Sloan Kettering Cancer Center (MSK) and is a member of the Molecular Pharmacology Program in the Sloan Kettering Institute (SKI), where he also serves as Deputy Director for Therapeutic Disovery. Additionally, Dr. Scheinberg founded and chairs the Experimental Therapeutics and formerly the Nanotechnology Center at MSK. He is a professor of medicine and pharmacology and co-chair of the pharmacology graduate program at Weill-Cornell Medical College and a professor at the Gerstner Sloan Kettering Graduate School. He founded and is a Director of the Tri-Institutional Therapeutics Discovery Institute of MSK, Cornell, and Rockefeller Universities.
From 1992 until 2002, Dr. Scheinberg was Chief of the Leukemia Service in Memorial Hospital and served as Chairman of Molecular Pharmacology from 2001 through 2022. He has been elected into the American Society of Clinical Investigation, the American Association of Physicians, and the Interurban Club. His other awards include the Doris Duke Distinguished Clinical Science Professorship, the Lucille P. Markey Scholarship, the Leukemia and Lymphoma Society Translational Investigator Awards, and CapCure Awards. He is an advisor to charitable foundations, cancer centers, and biotech companies.
My Role at MSK
A leukemia specialist is a doctor with special training in diagnosing and treating leukemia.
A physician-scientist is a doctor who also is a researcher.
Areas of Expertise
My Specialties
Acute and Chronic Leukemias
Immunotherapy
Monoclonal Antibodies
Cancer Vaccines
Education & Honors
Education
MD, PhD, The Johns Hopkins School of Medicine
Residencies
The New York Hospital/Cornell Medical Center
Fellowships
Memorial Sloan Kettering Cancer Center
Board Certifications
Internal Medicine
Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
Aetna
In Network Coverage Type HMO, EPO PPO, POS, Transplant
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Visit PubMed for a full listing of Dr. Scheinberg’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
We strive to keep reviews trustworthy, honest and fair.
Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David A. Scheinberg discloses the following relationships and financial interests:
Actinium Equity; Intellectual Property Rights; Professional Services and Activities
Arvinas, Inc. Equity
Atengen, Inc. Equity; Professional Services and Activities (Uncompensated)
Clade Therapeutics, Inc. Intellectual Property Rights
Eureka Therapeutics Inc Equity; Professional Services and Activities
Great Point Partners Equity; Professional Services and Activities
Iovance Biotherapeutics, Inc. Equity
Lantheus Medical Imaging, Inc. Equity
Lilly Oncology Equity
Pfizer, Inc. Equity
Repertoire Immune Medicines, Inc. Professional Services and Activities
Sapience Therapeutics, Inc. Equity; Fiduciary Role / Position
Sellas Life Science Group Equity; Fiduciary Role / Position; Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
